Upperton Pharma Solutions has expanded its production capabilities with the addition of a Fill2Weight gravimetric powder filling system at its Nottingham facility. The upgrade strengthens the company’s capacity for accurate and consistent powder dosing across multiple dosage forms, including oral, nasal, pulmonary, and parenteral products.
The Fill2Weight machine, developed by 3P innovation, uses a gravimetric dosing mechanism that ensures each capsule or device meets precise weight specifications. This capability supports complex and high-potency formulations, as well as projects involving limited-quantity active pharmaceutical ingredients.
The new system forms part of Upperton’s 60,000-square-foot GMP facility, which provides formulation development and clinical manufacturing services for small and mid-sized pharmaceutical companies. Its advanced dosing technology enables faster development cycles, allowing partners to progress from research to clinical trial stages with greater efficiency and reduced risk.
Ian Lafferty, Chief Technical Officer at Upperton, commented: “This addition marks a significant advancement in our GMP manufacturing capabilities, increasing our capacity to manufacture small-molecule and high potency medicines for clinical trials”.
Upperton continues to position itself as a key CDMO partner in the formulation and production of solid oral and dry powder medicines. The company’s investment in precision filling technology reinforces its commitment to supporting innovative drug development and manufacturing for the global pharmaceutical sector.
